LMR Partners’s UroGen Pharma URGN Stock Holding History

LMR Partners’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-13,746	Closed	-$127K	–	1122
2023 Q1	$127K	Buy	+13,746	New	+$126K	﹤0.01%	912

Other funds holding URGN

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

LMR Partners's URGN Position: Q2 2023 in Review

LMR Partners sold out of UroGen Pharma (URGN) in Q2 2023, closing a stake of 13,746 shares — an estimated $127K sold.

LMR Partners first reported a position in URGN in Q1 2023 and held it in 1 quarter. The position peaked at $127K in Q1 2023. 85 funds tracked by Wall St. Rank hold URGN as of Q2 2023.

LMR Partners reported no remaining UroGen Pharma position as of Q2 2023 after selling out during the quarter.
LMR Partners sold 13,746 UroGen Pharma shares in Q2 2023, an estimated $127K.
LMR Partners first reported a position in UroGen Pharma in Q1 2023 and held it in 1 quarter.
LMR Partners's UroGen Pharma position peaked at $127K in Q1 2023.
85 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2023.

Based on LMR Partners's 13F filing for Q2 2023, filed 14 Aug 2023.